Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Successful Treatment of Massive Intractable Pericardial Effusion with Tocilizumab in a Child Undergone Allogeneic Hematopoietic Stem Cell Transplantation
  • +2
  • Yue Li,
  • Xiaodong Wang,
  • Xiaohui Zhou,
  • Uet Yu,
  • Sixi Liu
Yue Li
Department of Hematology and Oncology Shenzhen Children’s Hospital
Author Profile
Xiaodong Wang
Department of Hematology and Oncology Shenzhen Children’s Hospital
Author Profile
Xiaohui Zhou
Department of Hematology and Oncology Shenzhen Children’s Hospital
Author Profile
Uet Yu
Department of Hematology and Oncology Shenzhen Children’s Hospital
Author Profile
Sixi Liu
Department of Hematology and Oncology Shenzhen Children’s Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

A 4-year-old child with β-thalassemia major underwent allogeneic hematopoietic stem cell transplantation (HSCT) on August 30, 2022 from a male haploidentical donor. He developed massive pericardial effusion (PE) secondary to a pulmonary infection. Methylprednisolone, tacrolimus discontinued, and pericardiocentesis were all ineffective. Since the interleukin-6 (IL-6) level in the PE was markedly increased (1868.58pg/ml), a total of two doses of tocilizumab was administered intravenously at a dosage of 5mg/kg every 2 weeks. PE remarkably reduced and completely resolved within 8 days. No recurrence of PE was observed in the follow up visits. Our results suggest that tocilizumab can be considered as a treatment of choice in massive PE after HSCT.